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Background: The aim of the study was to investigate how the expression of adhesion molecules changes as
neutrophils migrate from the circulation to the lung and if these changes differ between non-smoking subjects and
smokers with and without COPD.
Methods: Non-smoking healthy subjects (n=22), smokers without (n=21) and with COPD (n=18) were included.
Neutrophils from peripheral blood, sputum and bronchial biopsies were analysed for cell surface expression of
adhesion molecules (CD11b, CD62L, CD162). Serum, sputum supernatant and BAL-fluid were analysed for soluble
adhesion molecules (ICAM-1, -3, E-selectin, P-selectin, VCAM-1, PECAM-1).
Results: Expression of CD11b was increased on circulating neutrophils from smokers with COPD. It was also increased
on sputum neutrophils in both smokers groups, but not in non-smokers, as compared to circulating neutrophils.
Serum ICAM-1 was higher in the COPD group compared to the other two groups (p<0.05) and PECAM-1 was lower in
smokers without COPD than in non-smoking controls and the COPD group (p<0.05). In BAL-fluid ICAM-1 was lower in
the COPD group than in the other groups (p<0.05).
Conclusions: Thus, our data strongly support the involvement of a systemic component in COPD and demonstrate
that in smokers neutrophils are activated to a greater extent at the point of transition from the circulation into the
lungs than in non-smokers.
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Chronic obstructive pulmonary disease (COPD) is charac-
terised by a chronic airway inflammation, tissue destruc-
tion and irreversible airflow obstruction. Neutrophils are
one of the main effector cells in COPD and there are nu-
merous studies that show increased neutrophil numbers in
bronchoalveolar lavage (BAL) fluid, sputum, in bronchial
biopsies and blood [1-4]. Thus, the inflammatory process
in COPD is not only localised to the lungs and COPD is
today generally recognised as a systemic disease [5].
Neutrophils are one of the first cells to arrive at the
site of infection where they exhibit a broad functional* Correspondence: Kristin.Blidberg@ki.se
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reproduction in any medium, provided the orrepertoire in counteracting harmful agents. The migra-
tion of the neutrophils from the circulation to the site of
infection or injury is a carefully regulated series of events
involving adhesion molecules, chemoattractants and cy-
tokines. The migration has been described as a multistep
process including slow rolling, adhesion strengthe-
ning, intraluminal crawling and finally paracellular, or
transcellular, migration through the endothelium [6].
The initial rolling is mediated by L-selectin (CD62L)
expressed on neutrophils, and E-selectin and P-selectin
expressed on the endothelium. The main ligand for
these selectins is P-selectin glycoprotein ligand (PSGL)-1
(CD162) expressed both on neutrophils and certain
endothelial cells. Next, firm adhesion is mediated
through, for example, macrophage antigen-1 (Mac-1/
CD11b) expressed on neutrophils and its ligandl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





No. 22 21 18
Age (years) 55.0 54.0 61.9
51.6-58.4 50.6-57.4 58.6-65.1
Gender (Female/Male) 7/15 11/10 13/5









0.77 -0.82 0.73-0.79 0.52-0.59
DLCO %predicted 91.8 73.2 48.2
84.9-98.7 67.3-79.1 40.3-56.1
Data are presented as mean and 95% confidence intervals.
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the endothelium [7]. The third step, intravascular craw-
ling involves CD11b and other β2-integrins [8]. Prior to
the final step, transendothelial migration, vascular cell
adhesion molecules (VCAM)-1 and ICAM-1 form so
called docking structures on the endothelial cells [7,8].
For the final transendothelial migration, interaction be-
tween two platelet/endothelial cell adhesion molecule
(PECAM)-1 expressed at the borders of the endothelial
cells and on neutrophils is essential [9,10].
In addition to its role as an adhesion molecule, CD11b
is used as a marker of neutrophil activation as its activa-
tion is linked to several neutrophil functions such as the
oxidative burst, phagocytosis and release of proteolytic
enzymes [11]. Studies showing increased neutrophil ex-
pression of Mac-1 in subjects with COPD have led to
the suggestion that neutrophils in COPD are activated
to a greater degree compared to neutrophils in healthy
subjects [12,13]. Our knowledge of adhesion molecule
function mainly stems from studies of vascular inflam-
mation and animal models, and the understanding of
their role and significance in COPD is limited.
In the current study, we examined the expression of
soluble adhesion molecules on neutrophils from differ-
ent compartments (blood, sputum, bronchoialveolar
(BAL) fluid and bronchial biopsies). Taken together, the
patterns observed in the different locations may provide
a better understanding of the alterations that occur in
the neutrophils during transition from the circulation to
the airway. Moreover, a further aim was to investigate
whether these neutrophil characteristics differ between
smokers with COPD, smokers without COPD and
healthy non-smokers.
Materials and methods
Subjects and study design
Twenty-two healthy non-smokers, 21 current smokers
without chronic airflow limitation and 18 current
smokers with COPD were recruited by advertisement in
daily press. Smokers were included in the COPD group
if post-bronchodilator FEV1 /FVC was < 0.7 and FEV1
was >40% of the predicted normal value. Smokers were
allocated to the non-COPD group if they had a post-
bronchodilator FEV1 /FVC of >0.70. Healthy never-
smokers with normal spirometry made up the control
group. A history of asthma or other pulmonary or aller-
gic disease constituted exclusion criteria (Table 1). The
patients were clinically stable at the time of the study
and were not included if they had experienced an airway
infection during the past 14 days prior to the study. In
the COPD group 7 subjects inhaled tiotropium and 6
subjects inhaled a combination of steroids and long-
acting beta-agonists on a regular basis. All medication
was withheld 48 hours prior to the investigations.Blood samples were collected from all subjects and 12
subjects from each group underwent bronchoscopy, in-
cluding bronchoalveolar lavage followed by at least three
biopsies, and sputum induction on two separate days.
There was a minimum of 10 days between bronchoscopy
and sputum induction.
The study was approved by the local ethics committee
at Karolinska Institutet, Stockholm, Sweden (D-nr 2005/
733-31/1-4) and all subjects provided their written in-
formed consent.
Bronchoalveolar lavage (BAL) and biopsies
Bronchoscopy was performed as previously described [14].
After pre-medication with scopolamine, analgesics and
local anaesthesia with xylocaine the bronchoscope was
wedged in a middle lobe segmental bronchus and 5 ali-
quots of 50 mL isotonic saline were instilled into the air-
way tree and gently sucked back. The 5 aliquots of lavage
fluid were pooled and then centrifuged. The supernatant
was divided into aliquots and kept at -70°C until analysis.
Slides were also prepared by cyto-centrifugation and
stained using May-Grünwald Giemsa reagent. Bronchial
mucosal biopsies were taken from the subcarinas of an
upper lobe segment.
Sputum induction and processing
Sputum induction was performed as previously described
[15]. The cell-pellet was re-suspended in 2 mL PBS and
kept on ice until antibody staining for flow cytometric ana-
lysis. Slides were also prepared by cyto-centrifugation and
stained using May-Grünwald Giemsa reagent. For differen-
tial cell counts 300 non-squamous cells were assessed.
Blood
Peripheral blood was drawn in ethylene diamine-tetra-
acetic acid (EDTA) vacutainer tubes (BD Biosciences,
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surface markers and differential cell counts and in
vacutainer tubes without anticoagulant (BD Biosciences)
for serum analysis of soluble adhesion molecules. For dif-
ferential cell counts MultiTEST CD45PerCP/CD3FITC/
CD4APC/CD8PE (BD Bioscience) and TruCOUNT™
tubes (BD Biosciences) were used according to the manu-
facturer’s instructions. Absolute counts of lymphocytes,
monocytes, neutrophils, eosinophils and basophils were
determined by analysis in MultiSET (BD Biosciences).
Adhesion molecules on peripheral blood and sputum
neutrophils
Whole blood and sputum cells were stained with titrated
amounts of anti-CD11b PE, anti-CD62L PE or anti-CD162
PE together with anti-CD45 PerCp. Isotype matched anti-
bodies were used as negative controls. All antibodies were
from BD Biosciences. Samples were analysed using a
FACS Calibur™ (BD Biosciences) flow cytometer with
CellQUEST™ software. Results are presented as mean
fluorescence intensity (MFI=monoclonal antibody - matched
isotype control).
Soluble adhesion molecules
Soluble adhesion molecules were analysed in subjects
where representative samples from all three compart-
ments (serum, sputum supernatant, BAL fluid) were
obtained (n=12).
Soluble adhesion molecules were analysed in serum,
sputum supernatants and BAL-fluid (only ICAM-1)
using the Adhesion 6-plex FlowCytomix™ Multiplex kit
(Bender Medsystems, Vienna, Austria). Analyses were
performed according to the manufacturer’s instructions
using FACSCalibur™ flow cytometer (BD Biosciences) and
FlowCytomix Pro2.2 Software (Bender Medsystems, Vienna,
Austria). Detection ranges were as follows: sE-selectin:
4–3,000 ng/mL, sICAM-1: 5-4,000 ng/mL, sICAM-3: 11–
8,000 ng/mL, sPECAM-1: 4–3,000 ng/mL, sP-selectin: 19–
14,000 ng/mL and sVCAM-1 5-4,000 ng/mL.
The following adhesion molecules were analysed in
BAL fluid by Duo Set ELISA (RD Systems Europe,
Abingdon, UK ) according to the manufacturer’s instruc-
tions. The standard range was sE-selectin: 93–6,000
pg/mL, sICAM-3: 31–2,000 pg/mL, sP-selectin: 125–
8,000 pg/mL and sVCAM-1 31-2,000 pg/mL. Soluble
PECAM-1 was analysed using ELISA (Abnova, Taipei
City, Taiwan) according to the manufacturer’s instruc-
tions. The standard range was 156–10,000 pg/mL.
Processing and staining of bronchial biopsies
Biopsy specimens were embedded in glycol methacrylate
(GMA) and processed as previously described [16]. Se-
quential biopsy sections (2 μm) were cut from the GMA
blocks with a Leica RM 2165 microtome (LeicaMicrosystems, Germany) and floated onto 0.2% ammo-
nia solution prior to adherence to glass microscope
slides (Superfrost®, Thermo Scientific).
Biopsies were stained using the Envision kit (DAKO,
Sweden) according to the manufacturer’s instructions
with minor modifications. Briefly, incubation times for
the antibodies were increased to 1 hour and the double
stain block was extended to 5 minutes. The follo-
wing antibody dilutions were used: anti-neutrophil
elastase (NE) 1:300 (DAKO), anti-CD11b 1:200 (Abcam,
Cambridge, UK), anti-CD62L 1:100 (BioVision Research
Products, Mountain View, USA) and anti-CD162 1:200
(Epitomics, Burlingame, USA).
Statistics
Lung function data are presented as mean and 95% con-
fidence intervals. Data on cell distribution and adhesion
molecules are presented as median and interquartile
range. Comparisons between groups were made using
the Kruskal-Wallis test followed by a Mann–Whitney
test when appropriate and by Spearman Rank Order.
The Wilcoxon Signed Rank Test was used for within
group comparisons between compartments, these com-
parisons were made only in subjects with samples from
both of the relevant compartments.. A p-value below
0.05 was considered significant. For non-parametric stat-
istical calculations samples below the detection limit in
the Adhesion 6-plex FlowCytomix™ Multiplex kit were
assigned a value of 2 ng/mL. Data was analysed using
STATISTICA 9 (StatSoft, Inc., Sweden).
Results
Cell distribution in blood, sputum and BAL
The number of circulating neutrophils was significantly
higher in the COPD group compared to the group of
smokers without COPD (p=0.04) and healthy controls
(p=0.01, Table 2). The cell numbers and the cell distribu-
tion in sputum did not differ between the groups
(Table 2).
In BAL fluid, the numbers of macrophages and neu-
trophils were higher in the two smoker groups com-
pared to the non-smoking control group (p<0.05).
Furthermore, eosinophils were increased in the COPD
group compared to the non-smokers (p=0.01) and lym-
phocytes were increased in the group of smokers with-
out COPD as compared to the healthy non-smokers
(p=0.003, Table 2).
Adhesion molecules on blood and sputum neutrophils
Expression of CD11b was increased on blood neutro-
phils from COPD subjects compared to non-smoking
controls (p=0.01, Figure 1A). Moreover, CD11b expres-
sion on sputum neutrophils was higher in smokers with-
out COPD compared to the COPD group (p=0.02) and









Blood (cells x103/mL) Monocytes 512 597 ns 616 ns
363-741 482-674 516-790
Neutrophils 2914 3633 0.2 4072 0.01
2121-4188 2942-3889 3456-5392 *0.04
Lymphocytes 1828 2442 ns 2189 ns
1675-2752 1857-3148 1942-2624
Eosinophils 184 255 ns 269 ns
117-249 135-318 236-334
BAL (cells x106 /L) Cells x106/L 114 290 0.0001 281 0.002
83.2-129 259-523 156-351
Macrophages 91.3 264 0.0001 242 0.001
79.1-115.7 225-498 143-305
Neutrophils 3.8 12.4 0.03 8.4 0.04
0.4-5.1 3.5-21.5 3.6-21.7
Lymphocytes 4.7 13.3 0.003 10.2 0.2
3.6-8.9 11.2-23.5 3.3-19.8
Eosinophils 0 0 0.2 2.4 0.01
0-0.2 0-1.1 0.3-4.5
Sputum (cells/mg) Cells/mg 715 603 ns 652 ns
514-908 284-866 409-1370
Macrophages 250 218 ns 234 ns
155-603 53.5-444 136-424
Neutrophils 396 415 ns 501 ns
157-490 132-591 343-786
Lymphocytes 23.2 9.3 ns 14.9 ns
18.2-31.8 7.2-11.3 4.5-55.6
Eosinophils 0 1.3 ns 8.2 ns
0-5.0 0-2.6 0.6-16.8
Data are presented as median and 25th – 75th percentile. Comparisons between groups were made using Kruskal-Wallis test followed by Mann–Whitney test when
appropriate. * indicate p-value for comparison between smokers with and without COPD.
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nificant differences in CD62L or CD162 expression be-
tween the groups (Figure 1B, C).
Expression of CD11b was higher on sputum neutro-
phils compared to peripheral blood neutrophils from
smokers with (p=0.009) and without COPD (p=0.01).
There was no difference in CD11b expression between
the two compartments in the healthy controls. In con-
trast, expression of CD62L and CD162 was significantly
lower on sputum neutrophils compared to peripheral
blood neutrophils in all groups (p<0.05).
There was a negative correlation between expression of
CD11b on sputum neutrophils and FEV1/FVC in smokers
without COPD (Rho=−0.85, p=0.02) and a correlation be-
tween expression of CD11b on sputum neutrophils and
FEV1 (% predicted) in the COPD group (Figure 2).Soluble adhesion molecules
In serum the concentration of sICAM-1 was higher in
the COPD group than in the other two groups (p=0.02)
and sICAM-3 was higher in the COPD group than in
healthy non-smokers (p=0.005). Furthermore, sPECAM-
1 was lower in the smokers without COPD than in the
smokers with COPD (p=0.03). There were no other sig-
nificant differences between the groups with regard to
serum levels of soluble adhesion proteins (Figure 3).
In BAL-fluid sICAM-1 was lower in the COPD group
than in the other groups (p<0.05), also PECAM-1 was higher
in smokers without COPD compared to the other two
groups (p<0.05). Otherwise soluble adhesion molecules in
BAL fluid did not differ between the groups (Table 3). Sol-
uble E-selectin and P-selectin were only detectable in three




















































































Figure 1 Surface expression of adhesion molecules on blood and sputum neutrophils. Surface expression of A) CD11b, B) CD62L and C)
CD162 on blood neutrophils and sputum neutrophils measured by flow cytometry. Results are presented as mean florescence intensity (mfi).
P-values indicate comparisons between groups within the same compartment. Cell numbers were not sufficient for flow cytometric analysis in all
sputum samples, the analysed numbers are indicated in the figure.
Blidberg et al. Respiratory Research 2013, 14:47 Page 5 of 10
http://respiratory-research.com/content/14/1/47In sputum supernatants the levels of soluble adhesion
molecules did not differ between the groups (Table 3).
Bronchial biopsies
Bronchial biopsies from three subjects in each group
were double-stained and showed the presence of neutro-
phils expressing CD11b, CD62L and CD162. Representa-
tive images are displayed in Figure 4.0 200 400 600 800 1000 1200 1400 1600 1800 2000





























Figure 2 Correlations between lung function and CD11b expression o
expression in smokers without chronic airflow limitation. B: Relation between diseDiscussion
In the present study it was shown that CD11b expres-
sion on neutrophils is enhanced in association with their
transition from the blood to the airways in smokers.
This upregulation was observed irrespective of the pres-
ence of chronic airflow limitation, but was not shown in
non-smokers. Furthermore, CD11b expression on circu-
lating neutrophils was enhanced in patients with COPD0 200 400 600 800 1000 1200 1400 1600 1800 2000
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Figure 3 Soluble adhesion molecules in serum. Levels of soluble adhesion molecules A) ICAM-1, B) ICAM-3, C) PECAM-1, D) VCAM-1, E) E-
selectin and F) P-selectin measured in serum from controls (n=12), smokers without COPD (n=12) and smokers with COPD (n=12). Soluble
adhesion molecules were measured in subjects where samples from all compartments (blood, sputum and BAL) were available. Results are
presented as ng/mL. P-values indicate comparisons between groups.
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that even circulating neutrophils are activated in COPD
and that smoking is associated with a further activation
of airway neutrophils that is not observed in non-
smokers. In addition it was shown that, while CD11b ex-
pression is enhanced on airway neutrophils from
smokers, the expression of the adhesion proteins CD62L
and CD162 on neutrophils almost vanishes when enter-
ing the airways of both smokers and non-smokers. We
also showed that the levels of soluble ICAM-1 and
ICAM-3 in serum are increased in COPD, confirming
systemic inflammatory activity in this disease [17].
Although an increased CD11b expression on sputum
neutrophils has previously been shown in COPD [13]
this is, to our knowledge, the first time that CD11b ex-
pression in neutrophils has been studied in different
compartments within the same COPD patient. The two
groups of smokers are fairly well matched with regard to
cumulative tobacco exposure and there is a substantial
difference in lung function between the smokers with
and without COPD, indicating that comparisons be-
tween the smoker groups may be related to the presence
of airway obstruction. It is, however obvious that even
smokers who did not display chronic airflow limitation
and thus had not developed COPD according to current
diagnosis criteria, were not healthy as diffusion ca-
pacity was clearly impaired in this group compared
with healthy non-smokers. This finding indicates thatpathological processes in the lungs, as a consequence of
smoking, may develop along different lines in different
individuals.
Our data showed an increased CD11b expression on
sputum neutrophils from smokers without COPD and
that CD11b expression on sputum neutrophils exceeded
that of blood neutrophils in smokers, but not in non-
smokers. This likely indicates that neutrophils from
smokers, irrespective of airflow obstruction, become ac-
tivated in connection with the transition from the circu-
lation to the airways, a phenomenon that does not occur
in non-smokers. In addition, sputum neutrophils from
smokers without COPD are more activated than neutro-
phils from smokers with COPD. Smoke exposure of iso-
lated neutrophils in vitro activates neutrophils as it
causes increased expression of β2-integrin (CD18) and
decreased CD62L expression [18]. One may speculate
that the activation of sputum neutrophils caused by
smoking may be attenuated due to exhaustion of the im-
mune system in subjects with COPD, a speculation that
is supported by the finding of a correlation between
CD11b expression on sputum neutrophils and disease
severity, as assessed by FEV1 (% of predicted). In line
with this, expression of CD11b is down-regulated during
apoptosis and while the apoptosis rate of circulating
neutrophils has been shown to be unaltered in COPD,
an increased apoptosis rate has indeed been reported in
sputum neutrophils from subjects with COPD [19,20].
Table 3 Soluble adhesion molecules in BAL fluid and sputum
Controls Smokers without COPD Smokers with COPD
BAL fluid ICAM-1 94.8 94.3 47.6*, §
(ng/mL) 84.3-122.7 78.0-149.9 29.1-86.1
ICAM-3 15.1 16.1 12.4
(pg/mL) 9.6-26.2 8.7-26.1 10.6-18.8
PECAM-1 285.5 758.6§, 351.4*
(pg/mL) 194.2-684.1 525.7-1037.1 217.1-512.9
VCAM-1 281.5 122.4 114.4
(pg/mL) 118.5-484.9 103.9-204.7 75.2-293.9
Sputum supernatant (ng/mL) ICAM-1 16.6 16.6 33.6
<5.0-42.7 <5.0-34.4 <5.0-51.9
ICAM-3 17.1 20.3 28.7
14.1-60.5 <11.0-43.2 10.3-49.3
E-selectin < 4.0 < 4.0 12.5
<4.0-17.7 <4.0-13.0 <4.0-23.1
P-selectin < 19.0 < 19.0 < 19.0
<19.0 - 40.9 < 19.0 -25.5
PECAM-1 12.2 9.0 13.4
6.6-23.8 < 4.0-13.8 < 4.0-18.0
VCAM-1 7.1 < 5.0 8.5
5.1-7.8 <5.0-8.7 <5.0-12.0
Results are expressed as ng/mL; median and 25th- 75th percentiles.
§ p< 0.05 compared to non-smoking controls.
* p< 0.05 compared to smokers without COPD.
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have to be performed. Interestingly, FEV1/VC-ratio has
previously been shown to be inversely correlated with
CD11b expression on sputum neutrophils in subjects who
were current or ex-smokers, irrespective of significant air-
flow obstruction [13]. Our findings are in agreement with
these data in smokers without COPD, but are not con-
firmed in the smokers with COPD. This may lend further
support to the notion that sputum neutrophils from sub-
jects with COPD might have an impaired function com-
pared to neutrophils from smokers without COPD.
Neutrophil expression of CD11b does not only attract
attention as an adhesion molecule but it is also consid-
ered a marker of neutrophil activation. In the current
study we showed that CD11b expression is increased on
circulating neutrophils from subjects with COPD as
compared to healthy controls. This is in agreement with
earlier studies [12,21] and emphasises the systemic com-
ponent of the inflammation in COPD as we demon-
strated that even circulating neutrophils from patients
with COPD displayed signs of activation. Whereas ex-
pression of CD11b increase on activated neutrophils,
CD62L is shed upon activation [22]. Although there was
no difference in CD62L surface expression between the
groups in the current study, CD62L was significantlylower on neutrophils from sputum as compared to neu-
trophils from blood. Thus the CD62L data support the
CD11b data, and suggest that airway neutrophils are fur-
ther activated in relation to circulating neutrophils.
While neutrophil numbers in BAL fluid and sputum
are often increased in COPD, bronchial biopsies from
subjects with COPD show varying results with regard to
neutrophil numbers [1-3,23,24]. It has been hypothesised
that this discrepancy between different compartments is
due to the rapid migration of neutrophils through the
tissue in order to reach their primary destination in the
airway lumen. In addition, increased neutrophil numbers
have been suggested to be more characteristic of the in-
flammation present in the small airways [25,26]. In the
current study neutrophil numbers in BAL fluid were in-
creased and there was a similar trend in sputum.
Neutrophils expressing CD11b have previously been
shown to be increased in the submucosa of subjects with
COPD compared to control smokers [27]. In this study,
the presence of CD11b staining was confirmed and immu-
nohistochemical staining of bronchial biopsies showed
neutrophils expressing also CD62L and CD162.
In the current study, neutrophil expression of CD162
did not differ between the groups, but there was a lower




Figure 4 Expression of adhesion molecules in bronchial biopsies. Co-localisation of neutrophil elastase and A,B) CD11b, C,D) CD62L and E,F)
CD162 in bronchial biopsies from a patient with COPD. Neutrophil elastase positive cells are stained in brown; adhesion molecule positive cells are
stained in red. Arrows indicate cells double stained cells positive for neutrophil elastase and the respective adhesion molecule. Sections are
counterstained with haematoxylin. Original magnification for figure A, C and E is x200 and original magnification for B,E and F is x500.
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of subjects with varying stages of COPD (GOLD I-IV)
found increased CD162 expression on circulating neu-
trophils in the COPD group [28]. The ligand of CD162,
P-selectin, has received attention as a marker of platelet
activation and systemic inflammation. In one study it
was found that platelets were activated in COPD, but
this was not reflected by differences in soluble P-selectin
[29]. This is in line with the current results where no
differences in serum P-selectin were detected between
the groups. However, other studies support a role for P-
selectin as a marker of systemic inflammation in COPDand P-selectin has been associated with impaired lung
function in a large cross-sectional study [30]. Also,
Ferroni et al. found increased plasma levels of P-selectin
in subjects with COPD as well as an inverse relation be-
tween P-selectin and PaO2 [31]. It is possible that a lar-
ger sample size is needed to demonstrate a difference
between groups although this would also limit its useful-
ness as a marker of systemic inflammation.
E-selectin is only expressed on activated endothelium and
together with soluble ICAM-1 soluble E-selectin is some-
times considered a sign of endothelial activation. The per-
centage of E-selectin positive vessels in bronchial biopsies as
Blidberg et al. Respiratory Research 2013, 14:47 Page 9 of 10
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COPD [32,33]. However, the current study found no signifi-
cant difference in serum levels and it was below the detec-
tion limit in both sputum and BAL fluid samples.
Soluble ICAM-1 and sICAM-3 in serum were increased
in smokers with COPD as compared to healthy non-
smoking subjects. This finding is in agreement with those
of Riise et al. [32] who found increased levels of circulating
ICAM-1 in COPD patients with FEV1 between 60 and
70% of predicted value, i.e. similar to the patients in this
study. Walter et al. also found increased levels of soluble
ICAM-1 in serum from patients with moderate COPD,
FEV1 60 – 70% of predicted value [30]. Walter et al. also
found a relationship between circulating ICAM-1 levels
and disease severity, as assessed by FEV1 [30], but this as-
sociation was not demonstrated by Riise et al. [32]. In con-
trast to those findings Noguera et al. showed lower serum
levels of ICAM-1 in COPD than in healthy non-smokers
[21]. In that study patients with severe COPD, with FEV1
on average 33% of predicted value, were studied. The main
sources of ICAM-1 are bronchial epithelial cells and endo-
thelial cells [33,34]. Endothelial cells respond to pro-
inflammatory stimuli by an increased production of
sICAM-1 [34,35]. Elevated levels of TNF and other pro-
inflammatory cytokines is a common feature of COPD
which likely is of importance for the increased sICAM-1
levels observed in COPD. It could thus be hypothesised
that there is an association between disease severity and
the levels of ICAM-1 in mild and moderate COPD and
that severe COPD, characterised by loss of functional pul-
monary capillaries and airway mucosal cells, is associated
with decreased production and release of adhesion mole-
cules into the circulation.
Previously, Riise et al. showed an increase of sICAM-1 in
bronchial lavage fluid [32]. In agreement with this observa-
tion, a trend towards higher sICAM-1 levels was observed
in the sputum supernatants from the COPD group. Consid-
ering the 50-fold difference in volume between our BAL
technique and their small volume bronchial lavage it is rea-
sonable to relate the small volume bronchial lavage to spu-
tum supernatants as they both represent the central
airways. The role of sICAM-1 in the lung is not fully under-
stood but both human studies and animal models indicate
that alveolar epithelial cells are an important source of the
sICAM-1 found in BAL fluid [36]. Moreover, it has been
shown that sICAM-1 can induce neutrophil-mediated cyto-
toxicity [37] and activate lung macrophages [38]. It is there-
fore possible that the decreased sICAM-1 levels in BAL
fluid, observed in the COPD group, could be related to an
increased binding of sICAM-1 to different effector cells. In
addition, it appears that ICAM-1 is differentially regulated
in the bronchial epithelial cells and alveolar epithelial cells,
with a more marked increase of ICAM-1 in response to
stimuli observed in bronchial epithelial cells [36,39].Expression of PECAM-1 on the endothelium has been
shown to be of importance for transendothelial migration
of neutrophils as the blocking of PECAM-1 abolishes
transendothelial migration [40]. Soluble PECAM-1 can
bind endothelial PECAM-1 and thus prevent neutrophils
from transmigrating [40]. However, other adhesion mole-
cules have been shown to be involved in transmigration
and the adhesion molecules involved may change depend-
ing on stimulus and disease [41]. In the current study a
tendency towards lower serum sPECAM-1 in smokers
was found irrespective of airflow obstruction, with a sig-
nificantly lower level in smokers without COPD as com-
pared to the COPD group. It could be speculated that the
lower levels in the smoker group are caused by sPECAM-
1 binding to endothelial PECAM-1 as part of a protective
mechanism, a mechanism that has failed in the COPD
group. In BAL fluid sPECAM-1 was higher in smokers
without COPD as compared to both other groups.
The available literature on the role of soluble adhesion
molecules in COPD is contradictory. Most studies have
investigated serum levels; although some authors have
studied BAL fluid. There is large variation in severity of
disease between the studies and there is also a difference
in the techniques used to analyse the samples which
makes direct comparisons difficult.
In conclusion, our data show that neutrophils, from
COPD patients, retain, and further enhance, the state of ac-
tivation that is observed in circulation, even after migration
into the lungs. While the general role of soluble adhesion
molecules in COPD still requires further investigations,
some molecules, such as serum ICAM-1, appear to be reli-
able markers of the systemic inflammation in COPD.
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